Vertex Obsidian Therapeutics Ink Research Collaboration To Discover New Therapies That Regulate Gene Editing

Vertex Obsidian Therapeutics Ink Research Collaboration To Discover New Therapies That Regulate Gene Editing

By, Admin 27 April 2021

Vertex Pharmaceuticals Incorporated And Obsidian Therapeutics Announced That The Two Companies Have Entered Into A Strategic Research Collaboration And Licensing Agreement Focused On The Discovery Of Novel Therapies That Regulate Gene Editing For The Treatment Of Serious Diseases. The Collaboration Leverages Obsidian&Rsquo;S Cytodrive Platform Technology To Discover Gene-Editing Medicines Whose Therapeutic Activity Can Be Precisely Controlled Using Small Molecules And Vertex&Rsquo;S Established Scientific And Clinical Capabilities In Small Molecule, Cell And Genetic Therapies To More Rapidly Bring These Approaches To Patients.&Ldquo;This Collaboration With Obsidian Builds Upon And Will Expand Vertex&Rsquo;S Leadership In Small Molecule And Genetic Therapies, And We&Rsquo;Re Excited To Partner With The Team At Obsidian To Explore The Capabilities Of Their Technology,&Rdquo; Said Vertex&Rsquo;S David Altshuler, Executive Vice President, Global Research And Chief Scientific Officer. &Ldquo;The Ability To Tune Gene-Editing Activity To A Specific Level Is An Important Innovation That Has The Potential To Address Several Serious Diseases.&Rdquo;&Ldquo;At Obsidian, We&Rsquo;Re Using Our Cytodrive Technology To Pioneer A New Generation Of Engineered Cell And Gene Therapies For Patients With Serious Diseases,&Rdquo; Said Paul Wotton, Chief Executive Officer Of Obsidian Therapeutics. &Ldquo;Partnering With Vertex, An Established Leader At The Forefront Of Genetic Therapies, Will Further Advance Our Technology Into The Gene Therapy Field And Accelerate Development Of Controllable Gene Editing Therapies For Patients.&Rdquo;Under The Terms Of The Agreement, Obsidian Will Use Its Cytodrive Technology To Develop Novel Regulated Gene Editing Therapy Candidates For Multiple Serious Diseases. Obsidian Grants Vertex The Exclusive Option To License Worldwide Rights To Candidates Discovered And Developed Under The Collaboration. Following Vertex&Rsquo;S Exercise Of Its Options, Vertex Will Be Responsible For Further Preclinical And Clinical Development And Commercialization.Vertex Will Pay Obsidian Up To $75 Million In Upfront Payments And Research Milestones That May Be Paid During The Research Term, Including An Equity Investment In Obsidian. Obsidian Is Eligible To Receive Up To $1.3 Billion In Potential Payments Based Upon The Successful Achievement Of Specified Research, Development, Regulatory, And Commercial Milestones Across Up To Five Potential Programs. In Addition, Vertex Will Pay Tiered Royalties On Future Net Sales On Any Products That May Result From This Collaboration. Specific Diseases That Are The Subject Of This Collaboration Are Not Disclosed.Obsidian Therapeutics, Inc. Is A Biotechnology Company Pioneering Engineered Cell And Gene Therapies To Deliver Transformative Outcomes For Patients With Intractable Diseases.Vertex Is A Global Biotechnology Company That Invests In Scientific Innovation To Create Transformative Medicines For People With Serious Diseases. The Company Has Multiple Approved Medicines That Treat The Underlying Cause Of Cystic Fibrosis (Cf) &Mdash; A Rare, Life-Threatening Genetic Disease &Mdash; And Has Several Ongoing Clinical And Research Programmes In Cf.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!